Compare AstraZeneca plc (AZN) vs Salesforce Inc (CRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Salesforce Inc — how do they compare? AstraZeneca plc trades at $188.64 (market cap $290.69B), while Salesforce Inc trades at $215.53 (market cap $175.83B). The key difference: AstraZeneca plc is the larger of the two by market cap, and AstraZeneca plc pays the higher dividend (1.72%). Which is the better fit depends on your goals — on Pluang, investors hold AstraZeneca plc for 126 Days and Salesforce Inc for 89 Days on average.
| AZN | CRM | |
|---|---|---|
Market Cap | $290.69B | $175.83B |
Volume | 2,767,514 | 6,706,563 |
Sector | Health | Technology |
52-Week High | $209.48 | $266.23 |
52-Week Low | $155.62 | $150.12 |
Typical Hold Time | 126 Days | 89 Days |
Enterprise Value | $316.72B | $206.17B |
Dividend Yield | 1.72% | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $186.43, down 0.22% on the day, with strong fundamental performance including 17.68% net income margin and consistent earnings beats. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent developments include a $2 billion investment in Summit Therapeutics and expanded cancer drug collaborations, positioning the company for future growth in oncology treatments.
AstraZeneca presents a compelling investment case with robust profitability, strong analyst support (48.78% buy ratings), and strategic expansion in high-growth oncology markets. Key risks include execution challenges in clinical trials and competitive pressures in the pharmaceutical sector. The current price near the consensus target of $186.67 suggests balanced valuation with upside potential to the high target of $216.00.
Salesforce (CRM) trades at $215.45, up 0.84% with strong fundamentals including 77.28% gross margins and consistent earnings beats. The stock faces technical headwinds with bearish signals across moving averages and oscillators, trading near support at $214. Recent AI-driven growth initiatives show promise with Agentforce and Data 360 ARR reaching $2.9 billion, though sector-wide software selloffs have pressured valuations.
Wall Street maintains bullish sentiment with 76.5% buy ratings and $274.18 consensus target, representing 27% upside. Key risks include AI competition and macroeconomic volatility, but strong cash flow generation and expanding profit margins support long-term growth prospects despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
